Quinidine therapy in Brugada Syndrome

Phase 4

• Conditions: Brugada Syndrome; Cardiovascular - Other cardiovascular diseases

• Registration Number: ACTRN12620000934943
• Lead Sponsor: Sydney Local Health District

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2020-09-18
• Last Update Posted: 28 September 2020

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: All
• Target Recruitment: 15

Inclusion Criteria

Diagnosis of Brugada Syndrome

Exclusion Criteria

Current treatment with drug known to prolong QT interval
Baseline QTc >450msec for men, > 460msec for women
Baseline QRS > 130msec
Baseline PR >200msec
Patients taking medications known to interact with quinidine
Known hypersensitivity to quinidine

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Epicardial activation time by ECGi[Following 14+/- 7 days of quinidine therapy.];Epicardial recovery time by ECGi[Following 14+/- 7 days of quinidine therapy.];Temporal burden of type 1 Brugada pattern ECG on 12-lead Holter[Following 14+/- 7 days of quinidine therapy.]

Secondary Outcome Measures

Name	Time	Method
Reported tolerability of quinidine therapy as assessed by medication questionnaire (designed for this study) and self-reported adverse events.[Following 14+/- 7 days of quinidine therapy.]